Drug Profile
Paclitaxel nanopolymer - Samyang
Alternative Names: Paclitaxel PNPLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea
- 01 Aug 2012 Nanopolymer paclitaxel is available for licensing worldwide as of 01 Aug 2012. http://www.samyangbiopharm.com
- 01 Aug 2012 Preclinical trials in Cancer in South Korea (unspecified route)